{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "ca8b5026-37eb-4fb6-ba3f-6c9a4a9c3f4c",
   "metadata": {},
   "outputs": [],
   "source": [
    "import torch\n",
    "from utils.app_config import BaseAppConfig\n",
    "from db_connectors.postgres_connection import BasePostgreSQLConnectionHandler\n",
    "from retrievers.base_retriever import BaseDocumentRetriever\n",
    "\n",
    "from readers.reader_factory import ChatModelFactory\n",
    "from evaluation.retrieval_evaluation import evaluate_retriever_from_evaldata"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ebb26523-9598-4768-a239-0c6c4cd36f11",
   "metadata": {},
   "source": [
    "## Exploration utility to see the distribution of the Hard Negatives mined Compared to Positives"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "57801c79-10aa-4e2c-8178-ecaa65e7b3f6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "all_pos_scores = []\n",
    "all_neg_scores = []\n",
    "\n",
    "file_path = \"data/train/input_train_data_minedHN_scored.jsonl\"\n",
    "\n",
    "with open(file_path, \"r\", encoding=\"utf-8\") as f:\n",
    "    for line in f:\n",
    "        example = json.loads(line)\n",
    "        all_pos_scores.extend(example[\"pos_scores\"])\n",
    "        all_neg_scores.extend(example[\"neg_scores\"])\n",
    "\n",
    "plt.hist(all_pos_scores, bins=20, alpha=0.5, label='Positives')\n",
    "plt.hist(all_neg_scores, bins=20, alpha=0.5, label='Negatives')\n",
    "plt.legend()\n",
    "plt.title(\"Teacher Score Distribution\")\n",
    "plt.xlabel(\"Score\")\n",
    "plt.ylabel(\"Frequency\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6f5915ff-120f-4541-8913-1965efd22992",
   "metadata": {},
   "source": [
    "## Sample usage of classes based on a configuration set by a embedding model, a reranker optionally and a reader model."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "31338a80-38e7-49e2-8ec0-efad90d8957e",
   "metadata": {},
   "outputs": [],
   "source": [
    "config = BaseAppConfig()\n",
    "embedding_config = config.embedder_config\n",
    "reranker_config = config.reranker_config\n",
    "reader_config = config.reader_config\n",
    "evaluator_llm_name = config.evaluator_llm_name\n",
    "evaluation_files_dir = config.evaluation_files_dir\n",
    "corpus_table = config.corpus_table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "5a085323-31bb-4872-9a03-a857d31684a6",
   "metadata": {},
   "outputs": [],
   "source": [
    "embed_config = {'name': 'src_bge_base_en_v15_hnsw',\n",
    "   'store_table': 'src_bge_base_en_v15_hnsw',\n",
    "   'embedding_dim': 768,\n",
    "   'model_config': {'device': 'cuda',\n",
    "    'use_meta': False,\n",
    "    'trust_remote_code': True,\n",
    "    'use_fp16': True,\n",
    "    'model_name_or_path': 'BAAI/bge-base-en-v1.5',\n",
    "    'cache_dir': './models/cache/model',\n",
    "    'model_class': 'encoder-only-base'},\n",
    "   'text_splitter_config': {'chunk_size': 400,\n",
    "    'chunk_overlap': 50,\n",
    "    'separators': ['\\n\\n', '\\n', '. ', ' ', '']},\n",
    "   'index_config': {'name': 'hnsw',\n",
    "    'm': 16,\n",
    "    'ef_construction': 64,\n",
    "    'ef_search': 40}}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "38ca61a5-a7d5-4680-b732-3603399e62ab",
   "metadata": {},
   "outputs": [],
   "source": [
    "rerank_config = {'name': 'bge_reranker_base',\n",
    "   'model_name_or_path': './models/fine-tuned/bge_reranker_base/checkpoint-1000',\n",
    "   'cache_dir': './models/cache/model',\n",
    "   'model_class': 'encoder-only-base',\n",
    "   'use_fp16': True,\n",
    "   'trust_remote_code': True,\n",
    "   'device': 'cuda',\n",
    "   'batch_size': 16}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "457c9bad-75c0-4152-ac09-857f14306c58",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'OpenAI': [{'name': 'gpt-4o', 'model': 'gpt-4o', 'temperature': 0},\n",
       "  {'name': 'gpt-3.5-turbo', 'model_name': 'gpt-3.5-turbo', 'temperature': 0}],\n",
       " 'Anthropic': [{'name': 'claude-3-sonnet',\n",
       "   'model': 'claude-3-5-sonnet-20240620',\n",
       "   'temperature': 0}]}"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "reader_config"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "6ed1c5aa-e6cf-4ba4-b1c2-0590defd5d50",
   "metadata": {},
   "outputs": [],
   "source": [
    "indx_config = {'name': 'hnsw',\n",
    "    'm': 16,\n",
    "    'ef_construction': 64,\n",
    "    'ef_search': 40}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "b29dbd9d-1287-4d01-83fc-b67ccdbe74bd",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "`pooling_method` is not specified, use default pooling method 'cls'.\n",
      "`query_instruction_format` is not specified, set to default value '{}{}'.\n"
     ]
    }
   ],
   "source": [
    "db_con = BasePostgreSQLConnectionHandler(config.conn_config)\n",
    "\n",
    "\n",
    "retriever =  BaseDocumentRetriever(\n",
    "        db_con,\n",
    "        corpus_table,\n",
    "        embed_config.get(\"store_table\"),\n",
    "        embedding_config=embed_config.get(\"model_config\"),\n",
    "        reranker_config=rerank_config,\n",
    "        store_index_config=indx_config\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "6117d6c1-17b5-4848-9e40-c984ff22b70c",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/victor/Projects/tfm/readers/openai_chat_reader.py:8: LangChainDeprecationWarning: The class `ChatOpenAI` was deprecated in LangChain 0.0.10 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-openai package and should be used instead. To use it run `pip install -U :class:`~langchain-openai` and import as `from :class:`~langchain_openai import ChatOpenAI``.\n",
      "  self.llm = ChatOpenAI(**(model_config_kargs or {}))\n"
     ]
    }
   ],
   "source": [
    "system_prompt =\"\"\"Answer this question based on the provided context\n",
    "\"\"\"\n",
    "provider = \"OpenAI\"\n",
    "llm_config = {'name': 'gpt-4o', 'model': 'gpt-4o', 'temperature': 0}\n",
    "\n",
    "reader = ChatModelFactory.get_model(system_prompt, provider, llm_config)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "6d368f3a-540c-4005-9ba8-9366fa1d5e8c",
   "metadata": {},
   "outputs": [],
   "source": [
    "query = \"Concizumab is used for which diseases?\"\n",
    "\n",
    "docs, _ = retriever.get_top_k_docs(query, 100) # unpack like this, always return the vector store latency when returning the similar records."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "d270fd2e-e8d5-4a26-a929-2298b7f78818",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'id': '37341887',\n",
       "  'content': 'Concizumab: First Approval.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.8674772055084603,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 27},\n",
       " {'id': '31394258',\n",
       "  'content': 'Concizumab is a humanized monoclonal antibody in clinical investigation directed against membrane-bound and soluble tissue factor pathway inhibitor (mTFPI and sTFPI) for treatment of hemophilia',\n",
       "  'chunk': 1,\n",
       "  'score': 0.8080936853736279,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 193},\n",
       " {'id': '33570646',\n",
       "  'content': 'Concizumab is a novel subcutaneous prophylactic therapy for hemophilia. It is a hemostatic rebalancing agent that binds to the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), one of the molecules that contributes to downregulation of coagulation thereby preventing TFPI from binding to and blocking the factor Xa (FXa) active site',\n",
       "  'chunk': 1,\n",
       "  'score': 0.8078865825465794,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 341},\n",
       " {'id': '37646676',\n",
       "  'content': 'Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration. A previous trial of concizumab (explorer4) established proof of concept in patients with hemophilia A or B with inhibitors.',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7929367679766374,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 287},\n",
       " {'id': '37646676',\n",
       "  'content': 'Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.790639681900247,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 58},\n",
       " {'id': '35465188',\n",
       "  'content': 'Concizumab is a monoclonal, humanized IgG4 antibody specific for the Kunitz-2 domain of Tissue Factor Pathway Inhibitor (TFPI). Preclinical studies in vitro or on animal models and in vivo have demonstrated the ability of concizumab to restore thrombin generation, promoting the establishment of a procoagulant action; all these results were subsequently confirmed in the studies of EXPLORER program',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7873241461074927,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 399},\n",
       " {'id': '30614620',\n",
       "  'content': '. SUMMARY: Background Concizumab is a monoclonal antibody (mAb) against tissue factor pathway inhibitor (TFPI), currently in clinical development as a subcutaneous prophylactic therapy for hemophilia\\xa0A/B with and without inhibitors. In patients with inhibitors, the treatment choice for breakthrough bleeding will comprise bypassing agents, e.g',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7841604698880549,\n",
       "  'beginoffset': 353,\n",
       "  'endoffset': 697},\n",
       " {'id': '33570646',\n",
       "  'content': 'Concizumab: a novel anti-TFPI therapeutic for hemophilia.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7817234353005266,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 57},\n",
       " {'id': '29845491',\n",
       "  'content': '. Concizumab is a monoclonal, humanised antibody, specific for the second Kunitz domain of TFPI that binds and inhibits FXa, abolishing the inhibitory effect of TFPI. Concizumab restored thrombin generation in FVIII and FIX deficient plasmas and decreased blood loss in a rabbit haemophilia model',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7810873702524086,\n",
       "  'beginoffset': 575,\n",
       "  'endoffset': 871},\n",
       " {'id': '33819375',\n",
       "  'content': 'The anti-tissue factor plasma inhibitor monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without inhibitors',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7804997028130286,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 184},\n",
       " {'id': '35465188',\n",
       "  'content': \"Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives.\",\n",
       "  'chunk': 0,\n",
       "  'score': 0.7803041557311857,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 148},\n",
       " {'id': '30137664',\n",
       "  'content': '. Conclusion explorer™3 data support further clinical development of concizumab for use in people with hemophilia, with or without inhibitors.',\n",
       "  'chunk': 7,\n",
       "  'score': 0.7779906720004731,\n",
       "  'beginoffset': 2084,\n",
       "  'endoffset': 2226},\n",
       " {'id': '30137664',\n",
       "  'content': 'A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7778622683058379,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 110},\n",
       " {'id': '28594458',\n",
       "  'content': 'Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7731759168059973,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 199},\n",
       " {'id': '29517971',\n",
       "  'content': '. fitusiran and concizumab). This review will focus on these innovative therapies, providing an update on their current stage of clinical development.',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7681728723653134,\n",
       "  'beginoffset': 661,\n",
       "  'endoffset': 811},\n",
       " {'id': '37341887',\n",
       "  'content': 'Concizumab (Alhemo™), a subcutaneously administered humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor (TFPI), binds to the Kunitz-2 domain of TFPI and prevents TFPI from binding to activated Factor X. Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7673805898632683,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 339},\n",
       " {'id': '31394258',\n",
       "  'content': 'A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7606694447184702,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 122},\n",
       " {'id': '25641556',\n",
       "  'content': 'Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7594857387580606,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 151},\n",
       " {'id': '30431213',\n",
       "  'content': 'Emicizumab: Review of the literature and critical appraisal.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7572357067507629,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 60},\n",
       " {'id': '28594458',\n",
       "  'content': 'Concizumab, a humanized monoclonal antibody against tissue factor pathway inhibitor (TFPI), is being developed as a subcutaneously (s.c.) administered treatment for haemophilia. It demonstrated a concentration-dependent procoagulant effect in functional TFPI assays; however, global haemostatic assays, such as the thrombin generation assay (TGA), offer a more complete picture of coagulation',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7569797066521117,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 392},\n",
       " {'id': '30137664',\n",
       "  'content': '. SUMMARY: Background Concizumab is a humanized mAb targeting tissue factor pathway inhibitor (TFPI), leading to enhanced thrombin generation (TG) potential. explorer™3 (NCT02490787) was a phase 1b, double-blind, multiple-dose escalation trial of subcutaneous concizumab in people with severe hemophilia A without inhibitors. Objectives The primary objective was to evaluate safety',\n",
       "  'chunk': 2,\n",
       "  'score': 0.753301402060833,\n",
       "  'beginoffset': 351,\n",
       "  'endoffset': 732},\n",
       " {'id': '31394258',\n",
       "  'content': '. Concizumab displays a non-linear pharmacokinetic (PK) profile due to mTFPI-mediated endocytosis and necessitates a high dose and frequent dosing to suppress the abundant sTFPI, a negative regulator of coagulation',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7528700214688419,\n",
       "  'beginoffset': 193,\n",
       "  'endoffset': 407},\n",
       " {'id': '37341887',\n",
       "  'content': '. In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. This article summarizes the milestones in the development of concizumab leading to this first approval for the treatment of hemophilia B.',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7490945343320269,\n",
       "  'beginoffset': 339,\n",
       "  'endoffset': 736},\n",
       " {'id': '35290453',\n",
       "  'content': '. Anti-drug antibodies developed in 25% of patients and were low titer and transient, with no observed clinical effect in most cases. Results of the main + extension parts of these trials were consistent with results of the main parts. Ongoing phase 3 trials will further evaluate concizumab as a once-daily, subcutaneous treatment across hemophilia subtypes',\n",
       "  'chunk': 5,\n",
       "  'score': 0.7482256158960227,\n",
       "  'beginoffset': 1335,\n",
       "  'endoffset': 1693},\n",
       " {'id': '28841363',\n",
       "  'content': 'Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA)',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7479257307500904,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 265},\n",
       " {'id': '35465188',\n",
       "  'content': \". Concizumab may represent a new opportunity for the treatment of persons with hemophilia, so there is much anticipation for the results of the ongoing trials still. This review retraces all the studies on concizumab published to date, with a brief discussion about the patient' perspectives.\",\n",
       "  'chunk': 2,\n",
       "  'score': 0.7474352404502891,\n",
       "  'beginoffset': 399,\n",
       "  'endoffset': 691},\n",
       " {'id': '29845491',\n",
       "  'content': 'Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7449516024221786,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 120},\n",
       " {'id': '31444162',\n",
       "  'content': 'Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7429200821191534,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 110},\n",
       " {'id': '20065633',\n",
       "  'content': 'Tocilizumab.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7428521133938717,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 12},\n",
       " {'id': '31444162',\n",
       "  'content': 'Results from the main parts (24 weeks) of 2 concizumab phase 2 trials are presented: explorer4 in hemophilia A (HA) or B (HB) with inhibitors (HAwI/HBwI) and explorer5 in HA',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7407640237695479,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 173},\n",
       " {'id': '33570646',\n",
       "  'content': '. In the ongoing concizumab phase 3 trials, an optimized dosing regimen will be administered in patients with hemophilia A or B with and without inhibitors.',\n",
       "  'chunk': 6,\n",
       "  'score': 0.7399050379138068,\n",
       "  'beginoffset': 1560,\n",
       "  'endoffset': 1716},\n",
       " {'id': '35290453',\n",
       "  'content': 'Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7397907071232028,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 120},\n",
       " {'id': '31444162',\n",
       "  'content': '. Patients received 0.15 mg/kg concizumab, with potential dose escalation to 0.20 and 0.25 mg/kg (if ≥3 spontaneous bleeding episodes within 12 weeks of concizumab treatment). Relevant pharmacokinetic/pharmacodynamic (PK/PD) parameters were assessed. Thirty-six HA, 9 HAwI, and 8 HBwI patients were exposed to concizumab',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7381507406251314,\n",
       "  'beginoffset': 461,\n",
       "  'endoffset': 781},\n",
       " {'id': '31444162',\n",
       "  'content': '. Three patients had (very low to medium titer) ADA+ tests in each trial, with no observed clinical effect. These results support further development of concizumab as a daily prophylactic treatment in all hemophilia patients. These trials were registered at www.clinicaltrials.gov as #NCT03196284 and #NCT03196297.',\n",
       "  'chunk': 6,\n",
       "  'score': 0.7373034197194424,\n",
       "  'beginoffset': 1487,\n",
       "  'endoffset': 1801},\n",
       " {'id': '33570646',\n",
       "  'content': '. On the basis of phase 2 results, the US Food and Drug Administration granted concizumab Breakthrough Therapy designation for hemophilia B with inhibitor patients, a rare and vulnerable patient subgroup that currently has the highest unmet medical need',\n",
       "  'chunk': 5,\n",
       "  'score': 0.7365239361304002,\n",
       "  'beginoffset': 1307,\n",
       "  'endoffset': 1560},\n",
       " {'id': '29357074',\n",
       "  'content': 'Emicizumab-kxwh: First Global Approval.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7339094386702162,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 39},\n",
       " {'id': '28594458',\n",
       "  'content': '. We investigated how concizumab affects thrombin generation following ex vivo spiking in plasma from haemophilia patients using the TGA, and if the assay can detect the effect of multiple s.c. concizumab doses in healthy subjects.',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7336213433881804,\n",
       "  'beginoffset': 392,\n",
       "  'endoffset': 623},\n",
       " {'id': '31444162',\n",
       "  'content': '. The trials aimed to evaluate the efficacy of daily subcutaneous concizumab prophylaxis (evaluated as annualized bleeding rate [ABR] at last dose level), with secondary objectives being safety and immunogenicity (assessed as number of adverse events [AEs] and antidrug antibodies [ADAs])',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7335629408631468,\n",
       "  'beginoffset': 173,\n",
       "  'endoffset': 461},\n",
       " {'id': '30614620',\n",
       "  'content': '. In a safety study, cynomolgus monkeys were exposed to high steady-state concizumab concentrations and given three doses of rFVIIa, and then subjected to full necropsy and histopathological examination. Results In human blood, concizumab\\xa0+\\xa0rFVIIa had more pronounced procoagulant effects under hemophilic conditions than the sum of individual responses',\n",
       "  'chunk': 5,\n",
       "  'score': 0.7335041716672237,\n",
       "  'beginoffset': 1278,\n",
       "  'endoffset': 1631},\n",
       " {'id': '30137664',\n",
       "  'content': '. Results No serious AEs and no anti-drug antibodies were observed. Fifty-four mild and two moderate AEs were observed in 19 patients. Concizumab exposure increased with dose in a non-linear manner, confirming target-mediated drug disposition. D-dimer and F1 + 2 levels were increased mostly in the highest dose cohort, in line with previous observations',\n",
       "  'chunk': 5,\n",
       "  'score': 0.7334355593595937,\n",
       "  'beginoffset': 1434,\n",
       "  'endoffset': 1788},\n",
       " {'id': '30408848',\n",
       "  'content': 'Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7331715946313293,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 160},\n",
       " {'id': '35088769',\n",
       "  'content': 'Nonreplacement therapies, such as emicizumab (Hemlibra, Roche) and other myriad of molecules are still under study as concizumab (and other anti-TFPI) and fitusiran are transforming the quality of life and treatment of this group of patients',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7331112375295514,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 241},\n",
       " {'id': '31676141',\n",
       "  'content': '. Prophylaxis with subcutaneous long-acting non-factor products that improve in vivo thrombin generation is now under intensive investigation (concizumab, fitusiran) or successfully employed (emicizumab) in haemophilia patients. Both haemophilia patients with/without inhibitors take advantage of non-factor products employed alone',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7314875675512812,\n",
       "  'beginoffset': 218,\n",
       "  'endoffset': 549},\n",
       " {'id': '25641556',\n",
       "  'content': 'Prophylaxis with either intravenous (i.v.) factor VIII (FVIII) or FIX is the gold standard of care for patients with severe hemophilia. A monoclonal antibody (concizumab) targeting tissue factor pathway inhibitor (TFPI) that can be administered subcutaneously (s.c.) has the potential to alter current concepts of prophylaxis in hemophilia.',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7305667399845428,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 340},\n",
       " {'id': '30137664',\n",
       "  'content': 'Essentials explorer™3 was a double-blinded, multiple-dose escalation trial of subcutaneous concizumab. A pharmacodynamic relationship for unbound TFPI and thrombin generation was confirmed. No serious adverse events and no anti-drug antibodies were observed. explorer™3 data support further clinical development of concizumab in people with hemophilia',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7304530999349355,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 351},\n",
       " {'id': '30614620',\n",
       "  'content': '. In contrast, concizumab\\xa0+\\xa0rFVIIa had no additional effects on blood loss in hemophilic rabbits as compared with rFVIIa or concizumab alone. In cynomolgus monkeys, the macroscopic and microscopic pathological examinations revealed no thrombi or other signs of excessive coagulation activation',\n",
       "  'chunk': 6,\n",
       "  'score': 0.7299879774396911,\n",
       "  'beginoffset': 1631,\n",
       "  'endoffset': 1924},\n",
       " {'id': '35290453',\n",
       "  'content': '. Endpoints included annualized bleeding rate (ABR), adverse events (AEs), and occurrence of antidrug antibodies. Thromboembolic events were AEs of special interest. Thirty-six patients with HA, 15 with HAwI, and 10 with HBwI were exposed to concizumab',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7296082134982798,\n",
       "  'beginoffset': 734,\n",
       "  'endoffset': 986},\n",
       " {'id': '20402381',\n",
       "  'content': 'Recent years have seen many exciting developments in the treatment of inflammatory arthritis. Tocilizumab (TCZ) is a compound that inhibits the IL-6 receptor. Following initial studies in Japan, it has been extensively studied in five multicenter clinical trials',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7289238938522505,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 262},\n",
       " {'id': '33570646',\n",
       "  'content': '. Results from 2 phase 2 trials in patients with hemophilia A or B with and without inhibitors demonstrated that concizumab had a favorable safety profile, with no deaths, no thromboembolic events, and no adverse events leading to withdrawal',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7282064166193513,\n",
       "  'beginoffset': 737,\n",
       "  'endoffset': 978},\n",
       " {'id': '30137664',\n",
       "  'content': '. Assessments of pharmacokinetics, pharmacodynamics and subcutaneous concizumab immunogenicity were secondary objectives. Patients/Methods Adverse events (AEs), clinical assessments and bleeding episodes were recorded. Plasma concizumab levels and unbound TFPI levels were measured with ELISAs; residual TFPI activity was measured with a chromogenic assay',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7278562659430537,\n",
       "  'beginoffset': 732,\n",
       "  'endoffset': 1087},\n",
       " {'id': '30408848',\n",
       "  'content': 'Concizumab enhances thrombin generation (TG) potential in haemophilia patients by inhibiting tissue factor pathway inhibitor (TFPI). In EXPLORER3 (phase 1b), a dose-dependent pharmacokinetic/pharmacodynamic (PK/PD) relationship was confirmed between concizumab dose, free TFPI and TG potential.',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7278099698662882,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 294},\n",
       " {'id': '35290453',\n",
       "  'content': '. Here, we present results from extension parts of these trials, included to evaluate longer term safety and efficacy. Both trials included main (≥24 weeks) and extension (52-102 weeks) parts, with patients receiving concizumab 0.15 mg/kg with potential dose escalation to concizumab 0.20 or 0.25 mg/kg if they experienced ≥3 treated spontaneous bleeding episodes within 12 weeks',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7276566976791351,\n",
       "  'beginoffset': 355,\n",
       "  'endoffset': 734},\n",
       " {'id': '31394258',\n",
       "  'content': '. The obtained systems PK/PD model adequately described the PK of concizumab in rabbits, monkeys, and humans and the PD in humans. The systems PK/PD model predicted that an anti-TFPI recycling antibody with a 100-fold higher mTFPI/sTFPI dissociation constant in endosomes than concizumab can extend sTFPI suppression from 12\\u202fdays to 1\\u202fmonth',\n",
       "  'chunk': 6,\n",
       "  'score': 0.7274420311898975,\n",
       "  'beginoffset': 1209,\n",
       "  'endoffset': 1549},\n",
       " {'id': '24729685',\n",
       "  'content': '. Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody against the IL-6 receptor and has been approved in many countries, including the United States, for the treatment of moderate to severe RA in patients who have not adequately responded to one or more disease-modifying antirheumatic drugs (DMARDs) or cannot tolerate other approved drug classes for RA',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7251007397198099,\n",
       "  'beginoffset': 496,\n",
       "  'endoffset': 863},\n",
       " {'id': '28841363',\n",
       "  'content': 'Tocilizumab (Actemra).',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7225975359012424,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 22},\n",
       " {'id': '30137664',\n",
       "  'content': '. Standardized assays were used to assess TG, D-dimer and prothrombin fragment 1 + 2 (F1 + 2 ) levels. explorer™3 was completed after investigation of three dose cohorts (0.25, 0.5 and 0.8 mg kg-1 , once every 4 days) had been completed. Twenty-four patients received 12 doses of concizumab or placebo in a 3 : 1 randomization over a 42-day period',\n",
       "  'chunk': 4,\n",
       "  'score': 0.7204307955426382,\n",
       "  'beginoffset': 1087,\n",
       "  'endoffset': 1434},\n",
       " {'id': '30614620',\n",
       "  'content': '. activated recombinant FVIIa (rFVIIa) or activated prothrombin complex concentrates. Objectives To explore the effect and safety of concizumab and rFVIIa when they are simultaneously present',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7203444967769578,\n",
       "  'beginoffset': 697,\n",
       "  'endoffset': 888},\n",
       " {'id': '26751942',\n",
       "  'content': 'The recent development of biological agents, namely, anti-tumour necrosis factor alpha (TNF-α) agents (infliximab, adalimumab and etanercept), anti- CD20 monoclonal antibody (rituximab) and anti-interleukin 6 receptor (IL-6R) monoclonal antibody (tocilizumab), represents a major breakthrough for the treatment of immune-mediated disorders',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7200746205197935,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 339},\n",
       " {'id': '27182063',\n",
       "  'content': 'To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA).',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7193507912984022,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 86},\n",
       " {'id': '30614620',\n",
       "  'content': 'Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.718956981286055,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 157},\n",
       " {'id': '21234291',\n",
       "  'content': 'Recent years have seen many exciting developments in the treatment of rheumatoid arthritis. Tocilizumab (TCZ) is a monoclonal antibody which inhibits the interleukin-6 receptor. After initial studies in Japan, it has been extensively studied in five multicentre clinical trials. This report summarises the key efficacy and toxicity findings from the major clinical trials',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7177387612029204,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 371},\n",
       " {'id': '22870473',\n",
       "  'content': 'Tocilizumab (TCZ; RoActemra® or Actemra®) is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7166431989114623,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 145},\n",
       " {'id': '30559263',\n",
       "  'content': '. A new class of therapeutic agents that act by enhancing coagulation (emicizumab) and inhibiting anticoagulant pathways (fitusiran and concizumab) have been established, and clinical trials using these nonfactor products are ongoing',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7135319060387338,\n",
       "  'beginoffset': 697,\n",
       "  'endoffset': 930},\n",
       " {'id': '30614620',\n",
       "  'content': 'Essentials Hemophilia patients on concizumab prophylaxis may need rFVIIa to treat breakthrough bleeds. Effect and safety of concizumab\\xa0+\\xa0rFVIIa were tested in\\xa0vitro and in\\xa0vivo. Concizumab\\xa0+\\xa0rFVIIa had no additive effects on bleeding in hemophilic rabbits. High steady-state levels of concizumab did not affect the safety of rFVIIa in cynomolgus monkeys',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7131890051818494,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 353},\n",
       " {'id': '33819375',\n",
       "  'content': 'Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7128423309879326,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 125},\n",
       " {'id': '25630309',\n",
       "  'content': 'Tocilizumab (TCZ) and tumour necrosis factor inhibitors (TNFi) are recommended for the treatment of rheumatoid arthritis (RA) in patients with inadequate response (IR) to prior disease-modifying antirheumatic drugs (DMARDs)',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7124705674368332,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 223},\n",
       " {'id': '30614620',\n",
       "  'content': '. Methods Human blood made hemophilic with a FVIII antibody was spiked with increasing concentrations of concizumab, rFVIIa, or concizumab and rFVIIa in combination, and this was followed by thrombin generation test or thromboelastography. Blood loss in hemophilic rabbits was measured when concizumab, rFVIIa or concizumab\\xa0+\\xa0rFVIIa was administered either before or during cuticle bleeding',\n",
       "  'chunk': 4,\n",
       "  'score': 0.7116337438687007,\n",
       "  'beginoffset': 888,\n",
       "  'endoffset': 1278},\n",
       " {'id': '29746266',\n",
       "  'content': 'Ibalizumab.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7084279990619194,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 11},\n",
       " {'id': '27182063',\n",
       "  'content': 'Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7080490617977756,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 86},\n",
       " {'id': '30278802',\n",
       "  'content': '. These inhibitor patients suffer from increased morbidity and mortality and there has been a major unmet need for novel therapeutic approaches. Recently, one such therapy, emicizumab, has been licensed in the United States',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7078339018396821,\n",
       "  'beginoffset': 396,\n",
       "  'endoffset': 619},\n",
       " {'id': '33570646',\n",
       "  'content': '. Clinical proof of concept in prevention of bleeding episodes was confirmed in both concizumab phase 2 trials across all hemophilia subtypes assessed, with a statistically significant and clinically relevant reduction in annualized bleeding rates observed in inhibitor patients compared to those who received on-demand treatment',\n",
       "  'chunk': 4,\n",
       "  'score': 0.7078004998855668,\n",
       "  'beginoffset': 978,\n",
       "  'endoffset': 1307},\n",
       " {'id': '20979549',\n",
       "  'content': 'Tocilizumab for the treatment of rheumatoid arthritis.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7077440617936096,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 54},\n",
       " {'id': '21154167',\n",
       "  'content': \". Following promising data from a recent pilot trial, XOMA was also planning a phase I/II trial of gevokizumab for the potential treatment of uveitis in patients with the vasculitic inflammatory disorder Behçet's disease and the autoinflammatory conditions familial cold autoinflammatory syndrome and Muckle-Wells syndrome.\",\n",
       "  'chunk': 4,\n",
       "  'score': 0.7077185863002401,\n",
       "  'beginoffset': 906,\n",
       "  'endoffset': 1229},\n",
       " {'id': '21154167',\n",
       "  'content': 'Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7073736928655153,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 133},\n",
       " {'id': '19368420',\n",
       "  'content': 'Tocilizumab: a review of its use in the management of rheumatoid arthritis.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7073097498924092,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 75},\n",
       " {'id': '26250536',\n",
       "  'content': '. Tocilizumab, an anti-interleukin-6 receptor antibody, successfully induced remission of fever and lymphadenopathy. However, severe thrombocytopenia persisted and she developed anasarca, ascites, and pleural effusion shortly thereafter. Rituximab, an anti-CD20 antibody, and glucocorticoid therapy provided no symptom relief',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7050961405790364,\n",
       "  'beginoffset': 752,\n",
       "  'endoffset': 1077},\n",
       " {'id': '29807376',\n",
       "  'content': '. Meanwhile, there are new drugs been licensed or within licensing process. Patients with atypical HUS can be treated successfully by the Complement inhibitor Eculizumab. In addition, there is a new inhibitor of von-Willebrand-Polymerisation available. Caplacizumab provides a significantly better remission and decrease in TMA-related death',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7043036312699377,\n",
       "  'beginoffset': 332,\n",
       "  'endoffset': 673},\n",
       " {'id': '31813786',\n",
       "  'content': '. Drugs targeting cytokines [anti-TNFα (Etanercept), and anti-IL-6 (Tocilizumab)], and RTX (a chimeric monoclonal antibody vs. CD20) have been used in GO, with promising results. Teprotumumab (a human monoclonal anti-IGF-1R blocking antibody) has been investigated in a trial, showing it was very effective in GO patients',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7040595293122007,\n",
       "  'beginoffset': 644,\n",
       "  'endoffset': 965},\n",
       " {'id': '32365119',\n",
       "  'content': 'Tocilizumab is a humanized monoclonal antibody that is approved for the treatment of different human inflammatory diseases, including rheumatoid arthritis and cytokine release syndrome. Tocilizumab binds to the interleukin-6 receptor (IL-6R) and thereby blocks signaling of the pro-inflammatory cytokine IL-6',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7039593928640601,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 308},\n",
       " {'id': '26886466',\n",
       "  'content': '. Bococizumab (RN316; Pfizer, New York, NY) is currently being studied in similar indications, with an estimated approval date in late 2016. The pharmacodynamic effects of PCSK9 inhibitors have been extensively studied in various patient populations',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7035381026804101,\n",
       "  'beginoffset': 579,\n",
       "  'endoffset': 828},\n",
       " {'id': '31444162',\n",
       "  'content': '. PK/PD results were as expected, with no difference between hemophilia subtypes for concizumab exposure, free tissue factor pathway inhibitor, thrombin generation, prothrombin fragment 1+2, and d-dimers. Concizumab was safe and well tolerated (no severe AEs, AE-related withdrawals, or thromboembolic events)',\n",
       "  'chunk': 5,\n",
       "  'score': 0.7031794173811857,\n",
       "  'beginoffset': 1178,\n",
       "  'endoffset': 1487},\n",
       " {'id': '29495891',\n",
       "  'content': '. Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6\\xa0receptor licensed in 2009 that has demonstrated clinical efficacy in various adult RA populations. RA management guidelines and recommendations consider TCZ as one of the bDMARDS indicated after methotrexate or other conventional synthetic DMARDs and/or TNF inhibitors failure in adult RA',\n",
       "  'chunk': 2,\n",
       "  'score': 0.7028459947590846,\n",
       "  'beginoffset': 302,\n",
       "  'endoffset': 658},\n",
       " {'id': '34581771',\n",
       "  'content': '. This video addresses thrombotic complication in 3 nonfactor products: (1) emicizumab, a bispecific antibody that mimics the cofactor activity of factor VIII; (2) fitusiran, an small interfering RNA that knocks down synthesis of antithrombin; and (3) concizumab, an antibody that blocks inhibition of factor Xa by tissue factor pathway inhibitor',\n",
       "  'chunk': 3,\n",
       "  'score': 0.7027682960948475,\n",
       "  'beginoffset': 506,\n",
       "  'endoffset': 852},\n",
       " {'id': '29337452',\n",
       "  'content': 'Ocrelizumab (Ocrevus), an anti-CD20 monoclonal antibody, has been approved for the treatment of multiple sclerosis. Eculizumab (Soliris) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis. A form of gene therapy, patisiran, has shown positive results in transthyretin familial amyloidosis',\n",
       "  'chunk': 1,\n",
       "  'score': 0.7027228912437724,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 350},\n",
       " {'id': '25079039',\n",
       "  'content': 'Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7018350622917113,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 79},\n",
       " {'id': '26600980',\n",
       "  'content': '. Recent studies have indicated that golimumab (another anti-TNF-α agent), tofacitinib (a Janus kinase inhibitor), and vedolizumab and etrolizumab (integrin antagonists), achieved good clinical remission and response rates in UC. Recently, golimumab and vedolizumab have been approved for UC by the United States Food and Drug Administration',\n",
       "  'chunk': 4,\n",
       "  'score': 0.7011843375657916,\n",
       "  'beginoffset': 893,\n",
       "  'endoffset': 1234},\n",
       " {'id': '30344994',\n",
       "  'content': 'The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.7007290725141575,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 151},\n",
       " {'id': '30614620',\n",
       "  'content': '. Both rFVIIa and concizumab caused increases in thrombin-antithrombin and D-dimer concentrations; this effect tended to be additive with concomitant administration. Conclusions Concizumab did not affect the potency or safety of rFVIIa in\\xa0vivo. These results support a clinical evaluation of rFVIIa at standard dose (90\\xa0μg\\xa0kg-1 ) to treat breakthrough bleeds in concizumab clinical trials.',\n",
       "  'chunk': 7,\n",
       "  'score': 0.7000855761505079,\n",
       "  'beginoffset': 1924,\n",
       "  'endoffset': 2313},\n",
       " {'id': '35869698',\n",
       "  'content': 'Some non-factor products that work by facilitating the coagulation pathway (emicizumab) and blocking the anticoagulant pathway (fitusiran, concizumab and marstacimab) for patients with haemophilia (H) have been developed, and clinical trials using these products are currently ongoing',\n",
       "  'chunk': 1,\n",
       "  'score': 0.6998815980510517,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 284},\n",
       " {'id': '24155139',\n",
       "  'content': 'Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.6996964097337917,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 83},\n",
       " {'id': '28745999',\n",
       "  'content': 'Trial of Tocilizumab in Giant-Cell Arteritis.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.6995840737943236,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 45},\n",
       " {'id': '35869698',\n",
       "  'content': '. Phase 3 clinical trials and long-term observations assessing emicizumab revealed tolerable safety and efficacy. However, thrombotic events have occurred in patients receiving these non-factor products. Furthermore, monitoring of the haemostatic function of these products with concomitant therapy is also required in clinical practice',\n",
       "  'chunk': 3,\n",
       "  'score': 0.6993416311190584,\n",
       "  'beginoffset': 667,\n",
       "  'endoffset': 1003},\n",
       " {'id': '30298461',\n",
       "  'content': 'Caplacizumab: First Global Approval.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.6988722668644929,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 36},\n",
       " {'id': '29685815',\n",
       "  'content': 'Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.6984514762301132,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 116},\n",
       " {'id': '24075627',\n",
       "  'content': '[Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review].',\n",
       "  'chunk': 0,\n",
       "  'score': 0.6979903142151092,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 122},\n",
       " {'id': '30799358',\n",
       "  'content': '. Results We enrolled 49 patients. Thirty patients received tumor necrosis factor inhibitors (TNFis), 12 received abatacept (ABT), and the remaining 7 received tocilizumab (TCZ). Seventeen patients had ILD, 10 had AD, and 6 had both AD and ILD before the initiation of bDMARDs',\n",
       "  'chunk': 3,\n",
       "  'score': 0.6978413673989476,\n",
       "  'beginoffset': 744,\n",
       "  'endoffset': 1020},\n",
       " {'id': '30278802',\n",
       "  'content': 'Emicizumab for hemophilia A with factor VIII inhibitors.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.697582027640828,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 56},\n",
       " {'id': '24729685',\n",
       "  'content': 'Tocilizumab in the treatment of rheumatoid arthritis and beyond.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.6975160291264392,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 64},\n",
       " {'id': '31172372',\n",
       "  'content': '. Bimekizumab is currently in clinical development for psoriasis, psoriatic arthritis, and ankylosing spondylitis, with promising results. In early clinical trials, bimekizumab demonstrated a rapid onset of action, good safety profile, and high tolerability by treated study participants',\n",
       "  'chunk': 4,\n",
       "  'score': 0.6974788102714202,\n",
       "  'beginoffset': 942,\n",
       "  'endoffset': 1229},\n",
       " {'id': '32088663',\n",
       "  'content': 'Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.',\n",
       "  'chunk': 0,\n",
       "  'score': 0.696357449406395,\n",
       "  'beginoffset': 0,\n",
       "  'endoffset': 297}]"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "240b84cb-6535-4c36-8f7d-eb3dfccee84f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Concizumab is used for the treatment of hemophilia.'"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "max_context_k = 5\n",
    "reader.answer(query, docs[:max_context_k])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "d6119058-0828-440d-b998-a3e387263026",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt =\"\"\"Answer this question based on the provided context\n",
    "\"\"\"\n",
    "provider = \"Anthropic\"\n",
    "llm_config = {'name': 'claude-3-sonnet',\n",
    "               'model': 'claude-3-5-sonnet-20240620',\n",
    "               'temperature': 0}\n",
    "\n",
    "reader = ChatModelFactory.get_model(system_prompt, provider, llm_config)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "31ad9242-94fb-4dee-ba59-6839de72a0d0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Based on the provided context, concizumab is primarily used for the treatment of hemophilia. Specifically:\\n\\n1. It is being investigated as a treatment for hemophilia, including hemophilia A and B.\\n\\n2. It is described as a novel subcutaneous prophylactic therapy for hemophilia.\\n\\n3. It is designed to achieve hemostasis (control of bleeding) in all hemophilia types.\\n\\n4. It has been studied in patients with hemophilia A or B with inhibitors.\\n\\nThe context indicates that concizumab is particularly useful in cases of hemophilia where patients have developed inhibitors, which are antibodies that can interfere with standard factor replacement treatments. Concizumab works by targeting the tissue factor pathway inhibitor (TFPI), which helps to rebalance the coagulation system in people with hemophilia, regardless of the specific type of hemophilia they have.'"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "max_context_k = 5\n",
    "reader.answer(query, docs[:max_context_k])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "ee31e6db-8593-43e6-aa56-3b17ebb761bd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['12B4_golden.json',\n",
       " '12B3_golden.json',\n",
       " '12B2_golden.json',\n",
       " '12B1_golden.json',\n",
       " 'training12b_new.json']"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "files = os.listdir(config.evaluation_files_dir)\n",
    "files"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "44ac68c1-16e3-4871-91e0-923db9a6732d",
   "metadata": {},
   "outputs": [],
   "source": [
    "path = os.path.join(config.evaluation_files_dir,'12B4_golden.json')\n",
    "\n",
    "\n",
    "#evaluate_retriever_from_evaldata(retriever, '12B4_golden.json', (5,10,15, 50), top_k=100, rerank_top_k=50, use_rerank=True, overlap_threshold=0.5)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
